Ryzneuta
Product Description
Menagen Pharmaceuticals
-
Country/Region:Oman
-
On CPHI since:2024
-
Certificates:1
-
Employees:100 - 249
Company types
Categories
Specifications
Menagen Pharmaceuticals
-
Country/Region:Oman
-
On CPHI since:2024
-
Certificates:1
-
Employees:100 - 249
Company types
More Products from Menagen Pharmaceuticals (4)
-
Product Darbegen
Indicated for Chronic Kidney Disease Anemia -
Product Ezirosy
Treatment for Dyslipidemia -
Product Nitisinone Menagen
Indicated for hereditary tyrosinemia type 1 -
Product Renagen
Indicated for hyperphosphatemia
Menagen Pharmaceuticals resources (2)
-
News taiba Make Strategic Investment in Immuneel Therapeutics to advance CAR T-cell Research and Make Therapies More Affordable
taiba has announced a strategic investment in Immuneel Therapeutics for $12 million. -
News Menagen and Pharmosa Announce In-Licensing Collaboration for Sustained-Release Inhaled Treprostinil Product in MENAT Region
Menagen exclusively licenses MENAT rights for inhaled formulation of treprostinil